• ces_web_banner_toner_news_902x1776
  • cartridgewebsite-com-big-banner-02-09-07-2016
  • ncc-banner-902-x-177-june-2017
  • 4toner4
  • banner-01-26-17b
  • 05 02 2016 429716a-cig-clearchoice-banner-902x177
  • mse-big-banner-new-03-17-2016-416716a-tonernews-web-banner-mse-212
  • clover-depot-intl-us-ca-email-signature-05-10-2017-902x1772
  • Print
  • 2toner1-2


 user 2003-09-27 at 4:02:00 pm Views: 159
  • #7445

    Canon U.S.A. and Liquent Announce High-Volume Printing Solutions for the Pharmaceutical Industry

    Liquent CoreDossier Now Supports Canon’s Market Share Leading imageRUNNER Devices

    In Responding to the Needs of Pharmaceutical companies to affordably assemble and print complex regulatory, and mission critical documents, Canon U.S.A., Inc., an industry leader in networked imaging solutions, and Liquent, Inc., the global leader in regulatory publishing, intelligence, and intellectual property solutions, today announced Liquent’s flagship CoreDossier product support for Canon’s imageRUNNER line of high-volume printing devices.

    Using CoreDossier Version 5.5.3, pharmaceutical and life science companies can now efficiently manage the process of submitting large technical documents in accordance with strict U.S., European, and Japanese requirements by printing them on Canon imageRUNNER 7200, 8500, 85, 105, 110, and Pro 150+ models. CoreDossier, in use at nearly 300 locations around the world, enables life sciences companies to assemble and organize large volumes of documents into compliant formats and then creates the appropriate output in both PDF and Postscript formats. Publications – or dossiers – created with Liquent’s products are often submitted to government agencies and include New Drug Applications, Common Technical Documents, Marketing Authorization Applications, and other reports.

    face=Arial color=#0000ff face=Arial color=#0000ff Read More